Tag Archives: patients

Soaring stocks and the reasons why (ASIA, INSM, SHLD)

Posted on January 20, 2012 by Cameron White

In this report: AsiaInfo-Linkage (NASDAQ:ASIA), Insmed (NASDAQ:INSM) and Sears Holdings Corporation (NASDAQ:SHLD).

AsiaInfo-Linkage (NASDAQ:ASIA) shares are trading over 20 percent higher today after the company announced that it has received a proposal to be taken private by Power Joy (Cayman) …

Posted in Latest Headlines, Reports | Tagged acquire, Arikace, Asia, AsiaInfo-Linkage, common stock, company, Eddie Lampert, Food and Drug Administration, INSM, Insmed, NASDAQ, NASDAQ:ASIA, NASDAQ:INSM, NASDAQ:SHLD, patients, Power Joy, premium, rally, report, retailer, Sears Holdings Corporation, shareholder, shares, SHLD, speculation, stock, trading | Comments Off

At the bell market buzz (SLXP, BZH, BAX)

Posted on December 20, 2011 by Cameron White

In this report: Salix Pharmaceuticals (NASDAQ:SLXP), Beazer Homes USA (NYSE:BZH) and Baxter International (NYSE:BAX).

Salix Pharmaceuticals (NASDAQ:SLXP) shares jumped over 9 percent higher today after the company reported positive phase-3 data for its Relistor drug which treats constipation in patients …

Posted in Latest Headlines, Reports | Tagged acquired, Analysts, BAX, Baxter International, Beazer Homes USA, BZH, Commerce Department, company, deal, downgrade, economists, firm, housing, HOV, Hovnanian Enterprises, KB Homes, KBH, marketing, milestones, NASDAQ, NASDAQ:SLXP, NYSE, NYSE:BAX, NYSE:BZH, NYSE:HOV, NYSE:KBH, patients, Phase 3, Progenics Pharmaceuticals, rating, RBC Capital, relistor, sales, Salix Pharmaceuticals, share, shares, SLXP, stock, top pick | Comments Off

Big time losers and the reasons why (TSRX, HAS, PLCE)

Posted on December 19, 2011 by Martin Timble

In this report: Trius Therapeutics (NASDAQ:TSRX), The Children’s Place Retail Stores (NASDAQ:PLCE) and Hasbro (NASDAQ:HAS).

Trius Therapeutics (NASDAQ:TSRX) shares have sank by more than 11 percent today after the company released the results from its Phase 3 trial of Tedizolid. …

Posted in Latest Headlines, Reports | Tagged Analysts, Buy, company, downgrade, earnings, efficiency, expectations, FDA, fiscal, forecast, HAS, hasbro, Jakks Pacific, NASDAQ, NASDAQ:HAS, NASDAQ:PLCE, NASDAQ:TSRX, patients, Perform, Phase 3 trial, PLCE, rating, report, sales, sector, stern agree, stock, stores, Tedizolid, The Children’s Place Retail Stores, Trius Therapeutics, TSRX | Comments Off

Big time losers and the reasons why (CMED, MTL, AFFY)

Posted on December 6, 2011 by Cameron White

In this report: China Medical Technologies (NASDAQ:CMED), Mechel (NYSE:MTL) and Affymax (NASDAQ:AFFY).

China Medical Technologies (NASDAQ:CMED) plummeted by more than 21 percent on Tuesday after an online research firm alleged that the company had defrauded its investors. Glaucus Research Group …

Posted in Latest Headlines, Reports | Tagged acquisition, AFFY, Affymax, alleged, Amgen, CEO, China Medical Technologies, CMED, coal mines, company, competitor, debt fears, defrauded, firm, Glaucus Research Group, investors, market, Mechel, MTL, NASDAQ, NASDAQ:AFFY, NASDAQ:CMED, NYSE, NYSE:MTL, patients, report, safety insprction, shut down, stock, treatment | Comments Off

What the fuss Navistar, Tiffany’s and Abbot Labs?

Posted on November 30, 2011 by Josie Middleton

In this report: Navistar International (NYSE:NAV), Tiffany’s (NYSE:TIF) and Abbott Laboratories (NYSE:ABT).

Navistar International (NYSE:NAV) shares rose by more than 6.4 percent on Wednesday after the company received an upgrade by an analysts at Goldman Sachs. The firm upgraded the …

Posted in Latest Headlines, Reports | Tagged Abbott Laboratories, ABT, analyst, approved, blood test, company, earnings, expected, firm, Food and Drug Administration, forecasted, Goldman Sachs, investment bank, Jerry Revich, luxury items, NAV, Navistar international, net income, NYSE, NYSE:ABT, NYSE:NAV, NYSE:TIF, outlook, patients, report, sell, share, shares, shoppers, TIF, Tiffany’s, upgrade, vitamin D | Comments Off

Big time losers and the reasons why (CLSN, GOLD, TX)

Posted on November 28, 2011 by Josie Middleton

In this report: Celsion Corp. (NASDAQ:CLSN), Randgold (NASDAQ:GOLD) and Ternium (NYSE:TX).

Celsion Corp. (NASDAQ:CLSN) is trading over 13 percent lower today after the company announced a unanimous recommendation by an independent data monitoring committee to continue and complete its phase …

Posted in Latest Headlines, Reports | Tagged agreements, Analysts, Celsion Corp., CLSN, company, deal, expected, fiscal, Gold, liver cancer, NASDAQ, NASDAQ:CLSN, NASDAQ:GOLD, NYSE, NYSE:TX, patients, premium, production, quarter, Randgold, recommendation, report, setbacks, stake, steelmaker, Techint, Ternium, ThermoDox, trading, TX, Usiminas | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.